← Leaderboards
Nancy S Shulman
Stanford University
$1,052,521
Attributed
$1,052,521
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $233.7K · FY2005–10$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,052,521 · 4
By mechanism
K08$588,600 · 1
P51$298,675 · 2
R03$165,246 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Brad Alan Grueter$6,648,107
- David Allenberg Katzenstein$5,157,240
- Rami Kantor$14,799,482
- Robert W Shafer$16,663,491
- Steven E Artandi$26,596,623
Others in their field
Top investigators on “Ccr5 Gene”
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,374,416
- James L Riley · University Of Pennsylvania$25,460,724
- Luis J. Montaner · Wistar Institute$23,438,014
- Michael R. Farzan · Boston Children'S Hospital$23,164,182
- Rama Rao Amara · Emory University$20,291,611
- Sean P. J. Whelan · Washington University$19,061,505
Research focus
Ccr5 GeneRna Directed Dna PolymeraseCesarean SectionMacacaInfantResearch PersonnelSite Directed MutagenesisTransmission ProcessMothersGrantPreventImmunologic Assay /TestDiagnosis Quality /StandardDoseInhibitor/AntagonistPrimatesRecombinant ProteinsReverse Transcriptase InhibitorsGene MutationNewborn InfantPharmacologyClinical ResearchHuman Immunodeficiency Virus 1California
Grant awards (9)
FEASIBILITY OF CCR5 INHIBITORS IN PREVENTING MATERNAL TO INFANT SIV TRANSMISSION$152,094
P51 · FY2010 · RR · contact PI
FEASIBILITY OF CCR5 INHIBITORS IN PREVENTING MATERNAL TO INFANT SIV TRANSMISSION$146,581
P51 · FY2009 · RR · contact PI
Feasibility of CCR5 Inhibitors in Preventing Maternal to Infant SIV Transmission$87,106
R03 · FY2009 · AI · contact PI
Feasibility of CCR5 Inhibitors in Preventing Maternal to Infant SIV Transmission$78,140
R03 · FY2008 · AI · contact PI
Non-nucleoside Reverse Transcriptive Hypersensitivity$122,040
K08 · FY2006 · AI · contact PI
Non-nucleoside Reverse Transcriptive Hypersensitivity$122,040
K08 · FY2005 · AI
Non-nucleoside Reverse Transcriptive Hypersensitivity$122,040
K08 · FY2004 · AI
Non-nucleoside Reverse Transcriptive Hypersensitivity$111,240
K08 · FY2003 · AI
Non-nucleoside Reverse Transcriptive Hypersensitivity$111,240
K08 · FY2002 · AI